Tmunity Therapeutics is a technology company.
Tmunity Therapeutics has raised $110.0M across 2 funding rounds.
Tmunity Therapeutics has raised $110.0M in total across 2 funding rounds.
Tmunity Therapeutics was a clinical-stage biotherapeutics company developing next-generation T-cell therapies, primarily CAR-T cell treatments for cancer, targeting solid tumors like prostate, lung, ovarian, melanoma, sarcoma, and hematologic malignancies.[1][2][4] It served cancer patients with unmet needs, solving challenges in accessing effective therapies through engineered T-cells with enhanced activation control, armored mechanisms, and scalable manufacturing, including off-the-shelf allogeneic options to reduce costs and logistics.[2][5] Founded with strong University of Pennsylvania ties, Tmunity raised over $231 million, advanced multiple programs to early human trials—including the first U.S. CRISPR-based T-cell dosing—but was acquired by Gilead's Kite Pharma in 2022, leading to Philadelphia operations shutdown and layoffs by mid-2025.[5][6]
Tmunity Therapeutics was founded in 2015 by University of Pennsylvania pioneers Carl June, MD (inventor of CAR-T therapy and director of Penn’s Center for Cellular Immunotherapies), Bruce Levine, PhD, James Riley, PhD, Anne Chew, PhD, along with Bruce Blazar, MD, and Yangbing Zhao, MD, PhD, to translate academic cell therapy innovations into clinic-ready treatments.[2][4][5] The idea emerged from Penn's labs, where June and Levine's work ignited CAR-T breakthroughs, evolving into a platform for engineered T-cell receptors, regulatory T-cells, and multi-armored CAR-Ts amid rising demand for solid tumor therapies.[1][2] Early traction included a unique Penn partnership for discovery, $100 million Series A in 2018, $75 million Series B in 2020 (totaling $231 million pre-COVID), and programs entering human trials, bolstered by CEO Usman “Oz” Azam from Novartis.[2][4][6][8]
Tmunity rode the cell therapy wave, expanding CAR-T from blood cancers to intractable solid tumors amid a market projected to grow with manufacturing innovations and allogeneic tech.[2][5] Timing aligned with post-2017 CAR-T approvals, fueling investor interest (a16z, Be The Match) in "Cellicon Valley" (Philadelphia), where Penn's ecosystem accelerated translation from lab to trials.[2][6][9] It influenced biotech by proving academic-commercial bridges work, pioneering CRISPR in humans, and highlighting acquisition trends—its 2022 Kite buyout by Gilead scaled programs globally but underscored Big Pharma consolidation risks, shifting influence to Kite's oncology pipeline.[5][6]
Post-acquisition, Tmunity's independent story ended with Kite absorbing its tech and founders as advisors, redirecting efforts to Gilead's global cell therapy scaling for solid tumors and beyond.[5][6] Trends like allogeneic CAR-T, AI-driven engineering, and manufacturing automation will shape Kite's integration of Tmunity assets, potentially yielding broader cancer cures despite Philly setbacks. Its legacy endures as a bridge from Penn's breakthroughs to commercial reality, reminding investors that biotech momentum thrives on founder vision meeting pharma muscle—positioning Kite to lead next-gen T-cells where Tmunity pioneered.
Tmunity Therapeutics has raised $110.0M in total across 2 funding rounds.
Tmunity Therapeutics's investors include Andreessen Horowitz, Cofounders Capital, The Column Group, Westlake Village BioPartners.
Tmunity Therapeutics has raised $110.0M across 2 funding rounds. Most recently, it raised $75.0M Series B in October 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2019 | $75.0M Series B | Andreessen Horowitz, Cofounders Capital, The Column Group, Westlake Village BioPartners | |
| Apr 1, 2018 | $35.0M Series A | The Column Group, Westlake Village BioPartners |